Genzyme

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...

Many Americans who watched President Donald Trump’s address to Congress this week were left curious about the story of Megan Crowley and her father John Crowley. Trump made a point to use the Crowley’s story as an example of the type of entrepreneurial spirit the government needs to...

Billionaire investor and corporate raider Carl Icahn has trained his eyes on Bristol-Myers Squibb Co (NYSE: BMY). A Wall Street Journal report revealed on Tuesday that Icahn has picked up a substantial stake in the pharma giant, although the report did not put a number to it. Does Icahn's...

Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) have appreciated 64.79 percent over the past month, with the share price almost at the 52-week high on December 4. Wedbush’s David M. Nierengarten initiated coverage of the company with an Outperform rating and price target of $36. The...

U.S. stocks were mostly higher on the final trading day of May, as both the S&P 500 and Dow indices close at record highs, despite disappointing consumer spending data reported on Friday morning. Loretta Mester, the soon to be Cleveland Fed President argued in a speech the importance of...

Shares of Genzyme (NASDAQ: GENZ) were on the move again today up 27c to settle at 70.38 on volume of 4.7 million shares a hair over average. The board of Genzyme revealed they are open tp a merger with Sanofi-aventis (NYSE: SNY) though are looking for a price greater than $69 a share. Today...

It’s unusual for analysts to upgrade the stock of an acquirer during merger talks. Especially since most analysts think that Sanofi Aventis (NYSE: SNY) will raise its bid for Genzyme (NASDAQ: GENZ) But S&P raised Sanofi to Buy from Hold yesterday. The upgrade was most likely a reaction to...

S&P entered into the Sanofi-Aventis (NYSE: SYN) – Genzyme (NASDAQ: GENZ) merger fray by downgrading shares of Genzyme, yesterday to Hold from Buy. S&P think the deal will get done at a higher price than the $69 a share, Sanofi has offered to purchase Genzyme. But after Genzyme’s 38% stock...

This Sunday morning French pharmaceutical company Aventis, revealed their official bid for Genzyme, (NASDAQ: GENZ). Looks like merger Monday will be living up to it's nick name tomorrow with this 38% premium bid. The 38% premium represents the move from the low 50$ level when the takeover...

S&P raised Genzyme (NASDAQ: GENZ) to a Buy from Hold in the Aug. 4, edition of The Outlook, based on reports that Sanofi Aventis (NYSE: SNF) is going to acquire Genzyme. In a related story, Shire’s CEO, Angus Russell said of the proposed merger, “I'm not sure it changes anything in regards to...